|
|
Blood, 1 October 2004, Vol. 104, No. 7, pp. 2172-2175.
Prepublished online as a Blood First Edition Paper on June 1, 2004; DOI 10.1182/blood-2003-12-4386.
Previous Article | Table of Contents | Next Article 
NEOPLASIA Brief report
Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator
Esther P.M. Tjin,
Patrick W.B. Derksen,
Hiroaki Kataoka,
Marcel Spaargaren, and
Steven T. Pals
From the Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands; and the Second Department of Pathology, Miyazaki Medical College, Kiyotake, Japan.
Multiple myeloma (MM) is a common hematologic neoplasm consisting of malignant plasma cells, which expand in the bone marrow. A potential key signal in the evolution of MM is hepatocyte growth factor (HGF), which acts as a potent paracrine and/or autocrine growth factor and survival factor for MM cells. Proteolytic conversion of HGF into its active form is a critical limiting step in HGF/MET signaling. Here, we show that malignant MM plasma cells convert HGF into its active form and secrete HGF-activator (HGFA), a serine protease specific for HGF activation. By using serine protease inhibitors and neutralizing antibodies, we demonstrate that HGFA produced by the MM cells is responsible for their ability to catalyze HGF activation. We, therefore, suggest that autocatalyzation of HGF conversion by MM cells is an important step in HGF/MET-induced myeloma growth and survival, which may have implications for the management of this incurable form of cancer. (Blood. 2004;104:2172-2175)

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y. Wu, C. Eigenbrot, W.-C. Liang, S. Stawicki, S. Shia, B. Fan, R. Ganesan, M. T. Lipari, and D. Kirchhofer
Structural insight into distinct mechanisms of protease inhibition by antibodies
PNAS,
December 11, 2007;
104(50):
19784 - 19789.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Stellrecht, C. J. Phillip, F. Cervantes-Gomez, and V. Gandhi
Multiple Myeloma Cell Killing by Depletion of the MET Receptor Tyrosine Kinase
Cancer Res.,
October 15, 2007;
67(20):
9913 - 9920.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Marchand-Adam, A. Fabre, A. A. Mailleux, J. Marchal, C. Quesnel, H. Kataoka, M. Aubier, M. Dehoux, P. Soler, and B. Crestani
Defect of Pro-Hepatocyte Growth Factor Activation by Fibroblasts in Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med.,
July 1, 2006;
174(1):
58 - 66.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. P. M. Tjin, R. W. J. Groen, I. Vogelzang, P. W. B. Derksen, M. D. Klok, H. P. Meijer, S. van Eeden, S. T. Pals, and M. Spaargaren
Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma
Blood,
January 15, 2006;
107(2):
760 - 768.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. P. M. Tjin, R. J. Bende, P. W. B. Derksen, A.-P. van Huijstee, H. Kataoka, M. Spaargaren, and S. T. Pals
Follicular Dendritic Cells Catalyze Hepatocyte Growth Factor (HGF) Activation in the Germinal Center Microenvironment by Secreting the Serine Protease HGF Activator
J. Immunol.,
September 1, 2005;
175(5):
2807 - 2813.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Terpos and M.-A. Dimopoulos
Myeloma bone disease: pathophysiology and management
Ann. Onc.,
August 1, 2005;
16(8):
1223 - 1231.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|